Trending NewsTrending NewsNASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $5.67 +0.07 (+1.25%) Closing price 04:00 PM EasternExtended Trading$5.74 +0.07 (+1.15%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Replimune Group Stock (NASDAQ:REPL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Replimune Group alerts:Sign Up Key Stats Today's Range$5.53▼$5.8250-Day Range$2.81▼$12.6352-Week Range$2.68▼$17.00Volume2.27 million shsAverage Volume17.49 million shsMarket Capitalization$442.60 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingHold Company Overview Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Read More Replimune Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreREPL MarketRank™: Replimune Group scored higher than 89% of companies evaluated by MarketBeat, and ranked 130th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingReplimune Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageReplimune Group has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Replimune Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($2.97) to ($2.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.80% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Replimune Group has recently increased by 165.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.28 Percentage of Shares Shorted28.80% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Replimune Group has recently increased by 165.71%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.13 News SentimentReplimune Group has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Replimune Group this week, compared to 7 articles on an average week.Search InterestOnly 26 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat FollowsOnly 17 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -39% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,157.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Replimune Group is held by insiders.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Stock News HeadlinesROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL5 hours ago | globenewswire.comREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm5 hours ago | prnewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 22 at 2:00 AM | American Alternative (Ad)Lost Money on Replimune Group, Inc.(REPL)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyAugust 22 at 4:41 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLAugust 22 at 10:00 AM | prnewswire.comShareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPLAugust 22 at 8:45 AM | prnewswire.comREPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitAugust 21 at 4:00 PM | globenewswire.comClass Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact The Gross Law FirmAugust 21 at 3:27 PM | globenewswire.comSee More Headlines REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $12.11 on January 1st, 2025. Since then, REPL stock has decreased by 53.2% and is now trading at $5.67. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) posted its earnings results on Thursday, August, 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.12. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Replimune Group's major shareholders? Top institutional investors of Replimune Group include Redmile Group LLC (5.98%), Marshall Wace LLP (2.39%), Geode Capital Management LLC (2.09%) and Sofinnova Investments Inc.. Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Sushil Patel, Pamela Esposito, Konstantinos Xynos, Tanya Lewis, Emily Luisa Hill, Christopher Sarchi and Andrew Schwendenman. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings8/07/2025Today8/22/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:REPL CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees210Year Founded2015Price Target and Rating Average Price Target for Replimune Group$7.67 High Price Target$22.00 Low Price Target$2.00 Potential Upside/Downside+33.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$247.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.34% Return on Assets-52.81% Debt Debt-to-Equity Ratio0.21 Current Ratio6.94 Quick Ratio6.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.31 per share Price / Book1.33Miscellaneous Outstanding Shares78,056,000Free Float73,997,000Market Cap$446.87 million OptionableOptionable Beta0.67 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:REPL) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.